• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Rheumatology

Show Search
Hide Search
  • About Us
    • Our History
    • Our Faculty
    • Rheumatology Fellowship
    • Administrative Core
    • Contact Us
    • eNews Signup
  • Make an Appointment
    • Clinic Information
    • Specialty Clinics
  • Our Research
    • Current Research Studies
    • Andrade Lab
    • Darrah Lab
    • Konig Lab
    • Rosen Casciola Lab
    • RDRCC
    • Bayview Immunomics Core (BIC)
  • Charitable Giving
    • Dr. John Welton Fellowship in Rheumatology
    • Dr. Ira T. Fine Discovery Fund
    • Dr. Nadia D. Morgan Memorial Fund
  • News
    • LEAP Magazine
  • Education
    • Advances in the Diagnosis and Treatment of the Rheumatic Diseases Course
    • RheumTV – Patient Education Video Library
Home / Research Studies / Efficacy and Safety of Tofacitinib in Patients with Refractory Dermatomyositis

Efficacy and Safety of Tofacitinib in Patients with Refractory Dermatomyositis

May 4, 2018 By Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

IRB: IRB00084227

Purpose of Study: Recruitment is underway in Baltimore for a research study of tofacitnib (a.k.a. Xeljanz®) for refractory dermatomyositis. This study will assess the efficacy and safety tofacitinib administered orally in patients with clinically active dermatomyositis who have shown inadequate response to corticosteroids or other first line immunosuppressive agents like methotrexate, azathioprine, or mycophenalate mofetil.

Eligibility Criteria:

Study volunteers must meet the following criteria:
  • Age > 18
  • Have a biopsy-proven diagnosis of dermatomyositis
  • Have active skin disease
  • Have refractory myositis defined by active disease despite 12 weeks of steroids and with failure of response to at least prednisone and 1 other first line immunosuppressive agent OR have demonstrated significant toxicity or intolerance to such therapies
  • Negative cancer screening
  • Willing to come in for 8 on-site visits over 5 months (not including optional 12-week extension)
  • Additional criteria apply and will be reviewed with the study team

Study Status:

Recruiting

Coordinator/Contact:

Myositis Center
(410) 550-1741

Principal Investigator:

Julie Paik, MD, MHS
Assistant Professor of Medicine

Dr. Paik’s clinical and research interests are focused on neuromuscular manifestations of autoimmune diseases, particularly in the areas of myositis and scleroderma. The focus of Dr. Paik’s current research efforts is in determining the mechanisms of muscle disease in scleroderma. Whereas her clinical practice is focused on the broad range of autoimmune and inflammatory muscle disease in rheumatology, there is a particular emphasis on the neuromuscular manifestations of scleroderma.

Use of this Site

All information contained within the Johns Hopkins Division of Rheumatology website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

RheumTV Logo

Rheum.TV is an educational platform created to help patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit RheumTV

Footer

Rheumatology Specialty Care Centers

  • Johns Hopkins Arthritis Center
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect with Us

  • Facebook
  • Twitter
  • YouTube
U.S. News and World Report Rankings Badge

Johns Hopkins Medicine

© 2023 Johns Hopkins Rheumatology - Patient Privacy